CJ-023,423
Drug75 mg BID
NCT Number: NCT00392080
CJ-023,423 is a new medication being developed as an anti-inflammatory agent for the treatment of the signs and symptoms of osteoarthritis (OA). The purpose of this study is to evaluate whether patients treated with CJ-023,423 for 7 days (14 doses) have fewer gastrointestinal ulcers compared to patients treated with naproxen and placebo.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 1
Pfizer Investigational Site, Anaheim, California, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
75 mg BID
placebo
naproxen
Time frame: 7 days
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Time frame: Duration of trial
Looking for future studies?
Notify MePfizer
Industry
A Multicenter, Randomized, Placebo And Active-Controlled Study Of The Effect Of CJ-023,423 On The Incidence Gastroduodenal Endoscopic Ulcers In Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06514755
Arthritis, Behavior
Zagazig, Egypt
View Trial DetailsNCT02108496
Arthritis, Joint Diseases
Indianapolis, Indiana, United States
View Trial DetailsNCT07660081
Arthritis, Body Weight
Bannu, KPK, Pakistan
View Trial DetailsNCT04637529
Agnosia, Arthritis
São Paulo, Brazil
View Trial Details